Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 83 entries
Sorted by: Best Match Show Resources per page
Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease.

Clinical & translational immunology

de Jong E, Lim A, Waterer G, Price P.
PMID: 25505947
Clin Transl Immunology. 2012 Nov 14;1(11):e2. doi: 10.1038/cti.2012.1. eCollection 2012 Nov.

Pulmonary infections with non-tuberculous mycobacteria (NTM) affect a subset of older individuals (mostly women) with no known immunological defects. As NTMs are intracellular pathogens, it is important to establish whether NTM disease is associated with defective production of Th1...

Cite
de Jong E, Lim A, Waterer G, et al. Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease. Clin Transl Immunology. 2012;1(11):e2doi: 10.1038/cti.2012.1.
de Jong, E., Lim, A., Waterer, G., & Price, P. (2012). Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease. Clinical & translational immunology, 1(11), e2. https://doi.org/10.1038/cti.2012.1
de Jong, Emma, et al. "Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease." Clinical & translational immunology vol. 1,11 (2012): e2. doi: https://doi.org/10.1038/cti.2012.1
de Jong E, Lim A, Waterer G, Price P. Monocyte-derived macrophages do not explain susceptibility to pulmonary non-tuberculous mycobacterial disease. Clin Transl Immunology. 2012 Nov 14;1(11):e2. doi: 10.1038/cti.2012.1. eCollection 2012 Nov. PMID: 25505947; PMCID: PMC4256549.
Copy Download .nbib Format: NLM
Application of the new ion trap detector in doping control.

Journal of pharmaceutical and biomedical analysis

de Jong EG, Maes RA, van Rossum JM.
PMID: 16867373
J Pharm Biomed Anal. 1988;6(6):987-93. doi: 10.1016/0731-7085(88)80121-3.

No abstract available.

Cite
de Jong EG, Maes RA, van Rossum JM. Application of the new ion trap detector in doping control. J Pharm Biomed Anal. 1988;6(6):987-93doi: 10.1016/0731-7085(88)80121-3.
de Jong, E. G., Maes, R. A., & van Rossum, J. M. (1988). Application of the new ion trap detector in doping control. Journal of pharmaceutical and biomedical analysis, 6(6), 987-93. https://doi.org/10.1016/0731-7085(88)80121-3
de Jong, E G, et al. "Application of the new ion trap detector in doping control." Journal of pharmaceutical and biomedical analysis vol. 6,6 (1988): 987-93. doi: https://doi.org/10.1016/0731-7085(88)80121-3
de Jong EG, Maes RA, van Rossum JM. Application of the new ion trap detector in doping control. J Pharm Biomed Anal. 1988;6(6):987-93. doi: 10.1016/0731-7085(88)80121-3. PMID: 16867373.
Copy Download .nbib Format: NLM
Shot-Noise Suppression in the Single-Electron Tunneling Regime.

Physical review letters

Birk H, de Jong MJ, Schönenberger C.
PMID: 10060341
Phys Rev Lett. 1995 Aug 21;75(8):1610-1613. doi: 10.1103/PhysRevLett.75.1610.

No abstract available.

Cite
Birk H, de Jong MJ, Schönenberger C. Shot-Noise Suppression in the Single-Electron Tunneling Regime. Phys Rev Lett. 1995;75(8):1610-1613doi: 10.1103/PhysRevLett.75.1610.
Birk, H., de Jong MJ, & Schönenberger, C. (1995). Shot-Noise Suppression in the Single-Electron Tunneling Regime. Physical review letters, 75(8), 1610-1613. https://doi.org/10.1103/PhysRevLett.75.1610
Birk, et al. "Shot-Noise Suppression in the Single-Electron Tunneling Regime." Physical review letters vol. 75,8 (1995): 1610-1613. doi: https://doi.org/10.1103/PhysRevLett.75.1610
Birk H, de Jong MJ, Schönenberger C. Shot-Noise Suppression in the Single-Electron Tunneling Regime. Phys Rev Lett. 1995 Aug 21;75(8):1610-1613. doi: 10.1103/PhysRevLett.75.1610. PMID: 10060341.
Copy Download .nbib Format: NLM
Andreev reflection in ferromagnet-superconductor junctions.

Physical review letters

Beenakker CW, de Jong MJ.
PMID: 10059084
Phys Rev Lett. 1995 Feb 27;74(9):1657-1660. doi: 10.1103/PhysRevLett.74.1657.

No abstract available.

Cite
Beenakker CW, de Jong MJ. Andreev reflection in ferromagnet-superconductor junctions. Phys Rev Lett. 1995;74(9):1657-1660doi: 10.1103/PhysRevLett.74.1657.
Beenakker, C. W., & de Jong MJ. (1995). Andreev reflection in ferromagnet-superconductor junctions. Physical review letters, 74(9), 1657-1660. https://doi.org/10.1103/PhysRevLett.74.1657
Beenakker, and de Jong MJ. "Andreev reflection in ferromagnet-superconductor junctions." Physical review letters vol. 74,9 (1995): 1657-1660. doi: https://doi.org/10.1103/PhysRevLett.74.1657
Beenakker CW, de Jong MJ. Andreev reflection in ferromagnet-superconductor junctions. Phys Rev Lett. 1995 Feb 27;74(9):1657-1660. doi: 10.1103/PhysRevLett.74.1657. PMID: 10059084.
Copy Download .nbib Format: NLM
PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective.

iScience

Orozco Morales ML, Rinaldi CA, de Jong E, Lansley SM, Gummer JPA, Olasz B, Nambiar S, Hope DE, Casey TH, Lee YCG, Leslie C, Nealon G, Shackleford DM, Powell AK, Grimaldi M, Balaguer P, Zemek RM, Bosco A, Piggott MJ, Vrielink A, Lake RA, Lesterhuis WJ.
PMID: 34984327
iScience. 2021 Dec 04;25(1):103571. doi: 10.1016/j.isci.2021.103571. eCollection 2022 Jan 21.

Mesothelioma is a cancer that typically originates in the pleura of the lungs. It rapidly invades the surrounding tissues, causing pain and shortness of breath. We compared cell lines injected either subcutaneously or intrapleurally and found that only the...

Cite
Orozco Morales ML, Rinaldi CA, de Jong E, et al. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. iScience. 2021;25(1):103571doi: 10.1016/j.isci.2021.103571.
Orozco Morales, M. L., Rinaldi, C. A., de Jong, E., Lansley, S. M., Gummer, J. P. A., Olasz, B., Nambiar, S., Hope, D. E., Casey, T. H., Lee, Y. C. G., Leslie, C., Nealon, G., Shackleford, D. M., Powell, A. K., Grimaldi, M., Balaguer, P., Zemek, R. M., Bosco, A., Piggott, M. J., Vrielink, A., Lake, R. A., & Lesterhuis, W. J. (2022). PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. iScience, 25(1), 103571. https://doi.org/10.1016/j.isci.2021.103571
Orozco Morales, M Lizeth, et al. "PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective." iScience vol. 25,1 (2022): 103571. doi: https://doi.org/10.1016/j.isci.2021.103571
Orozco Morales ML, Rinaldi CA, de Jong E, Lansley SM, Gummer JPA, Olasz B, Nambiar S, Hope DE, Casey TH, Lee YCG, Leslie C, Nealon G, Shackleford DM, Powell AK, Grimaldi M, Balaguer P, Zemek RM, Bosco A, Piggott MJ, Vrielink A, Lake RA, Lesterhuis WJ. PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. iScience. 2021 Dec 04;25(1):103571. doi: 10.1016/j.isci.2021.103571. eCollection 2022 Jan 21. PMID: 34984327; PMCID: PMC8692993.
Copy Download .nbib Format: NLM
Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic.

The British journal of dermatology

van Winden MEC, Klösters FM, Hamaker M, Olde Rikkert MG, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK.
PMID: 34698375
Br J Dermatol. 2021 Oct 26; doi: 10.1111/bjd.20833. Epub 2021 Oct 26.

Balancing the risk for under- and overtreatment in older adults with basal cell carcinoma (BCC) frequently proves challenging.

Cite
van Winden MEC, Klösters FM, Hamaker M, et al. Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic. Br J Dermatol. 2021;doi: 10.1111/bjd.20833.
van Winden, M. E. C., Klösters, F. M., Hamaker, M., Olde Rikkert, M. G., van de Kerkhof, P. C. M., de Jong, E. M. G. J., & Lubeek, S. F. K. (2021). Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic. The British journal of dermatology, . https://doi.org/10.1111/bjd.20833
van Winden, M E C, et al. "Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic." The British journal of dermatology vol. (2021). doi: https://doi.org/10.1111/bjd.20833
van Winden MEC, Klösters FM, Hamaker M, Olde Rikkert MG, van de Kerkhof PCM, de Jong EMGJ, Lubeek SFK. Optimizing shared decision-making in older adults with basal cell carcinoma: experiences from a specialized outpatient clinic. Br J Dermatol. 2021 Oct 26; doi: 10.1111/bjd.20833. Epub 2021 Oct 26. PMID: 34698375.
Copy Download .nbib Format: NLM
Joint species distribution modelling with the r-package Hmsc.

Methods in ecology and evolution

Tikhonov G, Opedal ØH, Abrego N, Lehikoinen A, de Jonge MMJ, Oksanen J, Ovaskainen O.
PMID: 32194928
Methods Ecol Evol. 2020 Mar;11(3):442-447. doi: 10.1111/2041-210X.13345. Epub 2020 Jan 23.

Joint Species Distribution Modelling (JSDM) is becoming an increasingly popular statistical method for analysing data in community ecology. Hierarchical Modelling of Species Communities (HMSC) is a general and flexible framework for fitting JSDMs. HMSC allows the integration of community...

Cite
Tikhonov G, Opedal ØH, Abrego N, et al. Joint species distribution modelling with the r-package Hmsc. Methods Ecol Evol. 2020;11(3):442-447doi: 10.1111/2041-210X.13345.
Tikhonov, G., Opedal, �. �. H., Abrego, N., Lehikoinen, A., de Jonge, M. M. J., Oksanen, J., & Ovaskainen, O. (2020). Joint species distribution modelling with the r-package Hmsc. Methods in ecology and evolution, 11(3), 442-447. https://doi.org/10.1111/2041-210X.13345
Tikhonov, Gleb, et al. "Joint species distribution modelling with the r-package Hmsc." Methods in ecology and evolution vol. 11,3 (2020): 442-447. doi: https://doi.org/10.1111/2041-210X.13345
Tikhonov G, Opedal ØH, Abrego N, Lehikoinen A, de Jonge MMJ, Oksanen J, Ovaskainen O. Joint species distribution modelling with the r-package Hmsc. Methods Ecol Evol. 2020 Mar;11(3):442-447. doi: 10.1111/2041-210X.13345. Epub 2020 Jan 23. PMID: 32194928; PMCID: PMC7074067.
Copy Download .nbib Format: NLM
Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia.

Clinical & translational immunology

Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung LC, Buzzai A, Wagner T, Wylie B, Fernandez S, Cruickshank M, Endersby R, Kees U, Waithman J.
PMID: 32695339
Clin Transl Immunology. 2020 Jul 16;9(7):e1151. doi: 10.1002/cti2.1151. eCollection 2020.

OBJECTIVES: Natural killer (NK) cells are an attractive source of cells for an 'off the shelf' cellular therapy because of their innate capacity to target malignant cells, and ability to be transferred between donors and patients. However, since not...

Cite
Foley B, Ta C, Barnes S, et al. Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. Clin Transl Immunology. 2020;9(7):e1151doi: 10.1002/cti2.1151.
Foley, B., Ta, C., Barnes, S., de Jong, E., Nguyen, M., Cheung, L. C., Buzzai, A., Wagner, T., Wylie, B., Fernandez, S., Cruickshank, M., Endersby, R., Kees, U., & Waithman, J. (2020). Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. Clinical & translational immunology, 9(7), e1151. https://doi.org/10.1002/cti2.1151
Foley, Bree, et al. "Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia." Clinical & translational immunology vol. 9,7 (2020): e1151. doi: https://doi.org/10.1002/cti2.1151
Foley B, Ta C, Barnes S, de Jong E, Nguyen M, Cheung LC, Buzzai A, Wagner T, Wylie B, Fernandez S, Cruickshank M, Endersby R, Kees U, Waithman J. Identifying the optimal donor for natural killer cell adoptive therapy to treat paediatric B- and T-cell acute lymphoblastic leukaemia. Clin Transl Immunology. 2020 Jul 16;9(7):e1151. doi: 10.1002/cti2.1151. eCollection 2020. PMID: 32695339; PMCID: PMC7365579.
Copy Download .nbib Format: NLM
Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin.

The Journal of dermatological treatment

Logger JGM, Peppelman M, van Erp PEJ, de Jong EMGJ, Nguyen KP, Driessen RJB.
PMID: 32189533
J Dermatolog Treat. 2020 Mar 19;1-9. doi: 10.1080/09546634.2020.1741501. Epub 2020 Mar 19.

No abstract available.

Cite
Logger JGM, Peppelman M, van Erp PEJ, et al. Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin. J Dermatolog Treat. 2020;1-9doi: 10.1080/09546634.2020.1741501.
Logger, J. G. M., Peppelman, M., van Erp, P. E. J., de Jong, E. M. G. J., Nguyen, K. P., & Driessen, R. J. B. (2020). Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin. The Journal of dermatological treatment, 1-9. https://doi.org/10.1080/09546634.2020.1741501
Logger, Jade G M, et al. "Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin." The Journal of dermatological treatment vol. (2020): 1-9. doi: https://doi.org/10.1080/09546634.2020.1741501
Logger JGM, Peppelman M, van Erp PEJ, de Jong EMGJ, Nguyen KP, Driessen RJB. Value of reflectance confocal microscopy for the monitoring of rosacea during treatment with topical ivermectin. J Dermatolog Treat. 2020 Mar 19;1-9. doi: 10.1080/09546634.2020.1741501. Epub 2020 Mar 19. PMID: 32189533.
Copy Download .nbib Format: NLM
A Network Analysis of Perioperative Communication Patterns.

AORN journal

Stucky CH, De Jong MJ, Kabo FW, Kasper CE.
PMID: 32463500
AORN J. 2020 Jun;111(6):627-641. doi: 10.1002/aorn.13044.

To foster teamwork, improve clinical excellence, and promote a culture of safety, perioperative leaders should have a clear understanding of the dynamics that affect clinician communication in the OR. We used social network analysis to characterize the typical OR...

Cite
Stucky CH, De Jong MJ, Kabo FW, et al. A Network Analysis of Perioperative Communication Patterns. AORN J. 2020;111(6):627-641doi: 10.1002/aorn.13044.
Stucky, C. H., De Jong, M. J., Kabo, F. W., & Kasper, C. E. (2020). A Network Analysis of Perioperative Communication Patterns. AORN journal, 111(6), 627-641. https://doi.org/10.1002/aorn.13044
Stucky, Christopher H, et al. "A Network Analysis of Perioperative Communication Patterns." AORN journal vol. 111,6 (2020): 627-641. doi: https://doi.org/10.1002/aorn.13044
Stucky CH, De Jong MJ, Kabo FW, Kasper CE. A Network Analysis of Perioperative Communication Patterns. AORN J. 2020 Jun;111(6):627-641. doi: 10.1002/aorn.13044. PMID: 32463500.
Copy Download .nbib Format: NLM
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.

Future oncology (London, England)

Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens FA.
PMID: 33849298
Future Oncol. 2021 Jul;17(21):2747-2758. doi: 10.2217/fon-2021-0140. Epub 2021 Apr 14.

No abstract available.

Cite
Puglisi M, Molife LR, de Jonge MJ, et al. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol. 2021;17(21):2747-2758doi: 10.2217/fon-2021-0140.
Puglisi, M., Molife, L. R., de Jonge, M. J., Khan, K. H., Doorn, L. V., Forster, M. D., Blanco, M., Gutierrez, M., Franklin, C., Busman, T., Yang, J., & Eskens, F. A. (2021). A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future oncology (London, England), 17(21), 2747-2758. https://doi.org/10.2217/fon-2021-0140
Puglisi, Martina, et al. "A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors." Future oncology (London, England) vol. 17,21 (2021): 2747-2758. doi: https://doi.org/10.2217/fon-2021-0140
Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, Blanco M, Gutierrez M, Franklin C, Busman T, Yang J, Eskens FA. A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol. 2021 Jul;17(21):2747-2758. doi: 10.2217/fon-2021-0140. Epub 2021 Apr 14. PMID: 33849298.
Copy Download .nbib Format: NLM
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab.

Drugs - real world outcomes

van Muijen ME, Atalay S, van Vugt LJ, Vandermaesen LMD, van den Reek JMPA, de Jong EMGJ.
PMID: 33778926
Drugs Real World Outcomes. 2021 Jun;8(2):163-172. doi: 10.1007/s40801-021-00227-w. Epub 2021 Mar 28.

BACKGROUND: Personal treatment goals have been systematically investigated in psoriasis patients with active but not in controlled disease.OBJECTIVES: To explore patient needs in psoriasis patients with controlled disease due to biologic therapy with adalimumab, etanercept or ustekinumab.METHODS: Treatment needs...

Cite
van Muijen ME, Atalay S, van Vugt LJ, et al. Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. Drugs Real World Outcomes. 2021;8(2):163-172doi: 10.1007/s40801-021-00227-w.
van Muijen, M. E., Atalay, S., van Vugt, L. J., Vandermaesen, L. M. D., van den Reek, J. M. P. A., & de Jong, E. M. G. J. (2021). Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. Drugs - real world outcomes, 8(2), 163-172. https://doi.org/10.1007/s40801-021-00227-w
van Muijen, Marloes E, et al. "Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab." Drugs - real world outcomes vol. 8,2 (2021): 163-172. doi: https://doi.org/10.1007/s40801-021-00227-w
van Muijen ME, Atalay S, van Vugt LJ, Vandermaesen LMD, van den Reek JMPA, de Jong EMGJ. Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab. Drugs Real World Outcomes. 2021 Jun;8(2):163-172. doi: 10.1007/s40801-021-00227-w. Epub 2021 Mar 28. PMID: 33778926; PMCID: PMC8128951.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 83 entries